NVAX Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Matrix-M Platform PartnershipsBroad adoption by major pharmaceutical companies supports Matrix-M’s strategic relevance beyond Novavax’s current COVID-19 product. Rights covering more than 30 infectious-disease and oncology experimentation areas create potential for diversified long-term partner activity.
Sanofi Partnership MilestonesThe Sanofi relationship provides meaningful commercial validation and identifiable milestone opportunities tied to combination-vaccine development and manufacturing technology transfer. These payments could extend liquidity while supporting broader market access and partnership economics.
Structural Cost ReductionA substantially lower operating cost base could improve the company’s ability to reach profitability at a smaller revenue scale. The planned reduction in expenses and headcount is a durable restructuring benefit if execution preserves the most valuable platform and partner programs.
Bears Say
Revenue And Earnings VolatilityThe sharp swing from strong 2025 profitability to TTM losses shows that earnings depend heavily on uneven milestones, product demand, and timing of partner activity. Such volatility makes forward cash generation less predictable and raises execution risk.
Weak Balance Sheet SolvencyNegative equity weakens the company’s financial cushion and limits flexibility during periods of weaker vaccine demand or delayed partnerships. Even with moderate absolute debt, liabilities represent a larger structural burden when the equity base remains deficient.
Ongoing Cash BurnMulti-year negative operating and free cash flow indicates that the current business has not yet consistently funded itself internally. Continued cash burn can increase reliance on milestone receipts, financing, or other external funding to sustain development.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Currently, no data Available
What is Novavax’s market cap?
Novavax’s market cap is CHF1.50B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2026. The company reported -CHF0.264 earnings per share for the quarter, beating the consensus estimate of -CHF0.313 by CHF0.049.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.18.
How many shares outstanding does Novavax have?
Novavax has 164,945,720 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -CHF0.264 in its last earnings report, beating expectations of -CHF0.313. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in CH:NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF8.88 (― Downside)
CHF8.88 (― Downside)
Blogger Sentiment
Bullish
CH:NVAX Sentiment 89%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.17%
12-Months-Change
Fundamentals
Return on Equity
159.85%
Trailing 12-Months
Asset Growth
-28.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly optimistic, emphasizing expanding Matrix-M partnerships, Sanofi commercial and combination-vaccine progress, encouraging oncology and C. difficile development, substantial cost reductions, improved 2026 guidance, and long-term profitability and cash-runway objectives. Negative items included the year-over-year revenue decline caused by a large prior-year milestone, a $53 million quarterly net loss, dependence on fourth-quarter COVID-19 revenue, potential future asset write-offs, and uncertainty around partner timelines and early-stage programs. The stated achievements and forward-looking catalysts significantly outweighed the challenges.View all CH:NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
CHF8.88
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―